Supyra®

S Kant Healthcare

Legend
Product category

  • Seasonal malaria chemoprevention (sulfadoxine-pyrimethamine + amodiaquine)
Therapeutic indication

  • Seasonal malaria chemoprevention for children 3 to 59 months in eligible region
Dosing

  • Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles for 4 months
Efficacy

  • 75% reduction in malaria episodes in pivotal trials
Key features

  • Recommended by WHO for the prevention of malaria in children in areas of high seasonal malaria transmission
Challenges
  • Drug distribution to healthy subjects mainly via door-to-door campaigns
Status
  • The Global Fund ERP approved for one year until Feb 2020
  • Registered in 5 countries; ongoing in 5 other countries
Next milestone

  • WHO prequalification
MMV Project Director

  • Dr André-Marie Tchouatieu